Page 2 - Gland Pharma

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Gland Pharma shares slip 5% on disappointing revenue growth in Q3

Analysts at InCred Equities said they are disappointed with the repeated delay in Cenexi's turnaround and will reassess the situation constructively once the facility is back on track

Gland Pharma Q3 result: Net profit rises 7% to Rs 205 cr as expenses drop

Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers saw muted growth in the North American market, including the US

USFDA issues Establishment Inspection Report to Gland Pharma; stock up 3%

The pharmaceutical company's shares were quoted at an all-time high of Rs 4,350 on August 21, 2021, while they touched their all-time low of Rs 861.50 on May 22, 2023

Stocks to Watch, Dec 26: IOC, Gland Pharma, BPCL, Ramky Infra, Ceigall

Stocks to watch on December 26, 2024: Indian Oil Corporation plans to sign an agreement with the Odisha government in January for a Naphtha Cracker Project at Paradip

Gland Pharma jumps 5% after USFDA nod for Vitamin-K deficiency drug

Shares of Gland Pharma surged up to 4.76 per cent at Rs 1860 on the BSE in the early morning trade of Thursday

Stocks to Watch, Dec 12: Jubilant FoodWorks, SBI, Vedanta, Swiggy, Emami

Stocks to Watch, Dec 12: From Swiggy to Jubilant Foodworks, here are some stocks that will be on investors radar today

Here's why Gland Pharma share was up 3% on December 3; details here

The uptick in Gland Pharma share came after the company said that it has received approval from the United States Food and Drug Administration (US FDA) for Latanoprost Ophthalmic Solution

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Upper-teens EPS growth likely for Gland Pharma in next two financial years

Analysts are downgrading optimistic EPS estimates for FY25 and FY26, due to continuing slowdown in US sales and a temporary issue at Cenexi's site in Belgium

Gland Pharma soars 13% on better than expected Q2 performance

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

Gland Pharma Q2FY25 results: Net profit falls 15.7% to Rs 164 crore

The company reported consolidated net profit of Rs 164 crore ($19.5 million) for the quarter ended Sept. 30, a 15.7 per cent decrease from the year-ago period

ACC, 2 pvt banks among 8 midcap stocks turn favourable on tech charts

The Nifty MidCap index has gained 3% from its recent low in the last three days. Amid this these 8 stocks have seen key momentum oscillators turn favourable on the daily chart.

Gland Pharma tanks 9% on weak June quarter show; Q1 profit drops 26%

The share price fell after the company reported a weak set of June quarter (Q1FY25) results.

Gland Pharma Q1 FY25 results: Net profit falls 26%, revenue rises 16%

The decrease in the group's consolidated Ebitda margin is being attributed to the negative Ebitda reported by Cenexi, its recent acquisition

Gland Pharma promoter Fosun divests 6% stake for Rs 1,754 cr via bulk deal

Fosun Pharma, one of the promoters of Gland Pharma, on Wednesday divested a 6 per cent stake for Rs 1,754 crore through an open market transaction. Chinese drug firm Fosun Pharma, through its arm Fosun Pharma Industrial Pte, offloaded the shares of Hyderabad-based Gland Pharma through a bulk deal on the BSE. According to the bulk deal data available on the BSE, Fosun Pharma Industrial Pte disposed of 99 lakh shares or a 6 per cent stake in Gland Pharma. The shares were sold at an average price of Rs 1,771.81 apiece, taking the deal size to Rs 1,754.09 crore. After the stake sale, Fosun Pharma's shareholding in Gland Pharma has declined to 51.86 per cent from 57.86 per cent. Meanwhile, UBS Principal Capital Asia picked up 8.25 lakh shares, amounting to a 0.5 per cent stake in Gland Pharma. The shares were purchased at an average price of Rs 1,771.05 per piece, taking the transaction value to Rs 146.11 crore. Details of the other buyers of Gland Pharma's shares could not be ...

Indus Towers, Tata Technologies among seven stocks to track on June 19

At 6:37 AM, GIFT Nifty futures indicated a robust start, trading up 85 points at 23,653 compared to Nifty futures' previous close

Gland Pharma surges 11% amidst stellar Q4 results; profits grow two fold

On Wednesday, Gland Pharma reported a two fold jump or 145 per cent increase in consolidated net profit, reaching Rs 192.4 crore for the January-March period of FY24

Gland Pharma Q4 results: Net profit jumps over two-fold to Rs 192 crore

Gland Pharma on Wednesday said its consolidated profit after tax (PAT) surged over two-fold to Rs 192 crore for the March quarter. The company has reported a PAT of Rs 79 crore in the year-ago period, the Hyderabad-based drug firm said in a statement. Revenue from operations rose to Rs 1,537 crore in the fourth quarter of FY24 as against Rs 785 crore in the year-ago period, it said. For the year ended March 31, 2024, the company reported a PAT of Rs 772 crore as against Rs 781 crore in 2022-23 fiscal. Revenue from operations rose to Rs 5,665 crore last fiscal as against Rs 3,625 crore in FY23. "This year marked a significant rebound for our base business, and we began an exciting new chapter as we completed our first international acquisition, Cenexi, in Europe," Gland Pharma MD and CEO Srinivas Sadu said. Despite the dynamic business landscape, the drugmaker has shown resilience and delivered a performance that positions it well for continued growth and success, he added. "We s

Private equity company Bain Capital sells residual stake in Axis Bank

Among the buyers were a clutch of domestic as well as foreign funds